2185 Stock Overview
Shanghai Bio-heart Biological Technology Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Shanghai Bio-heart Biological Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.71 |
| 52 Week High | HK$4.58 |
| 52 Week Low | HK$1.26 |
| Beta | -0.55 |
| 11 Month Change | -3.93% |
| 3 Month Change | 11.04% |
| 1 Year Change | -62.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.49% |
Recent News & Updates
We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth
Nov 15
Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans
Jul 24Recent updates
We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth
Nov 15Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans
Jul 24Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth
Feb 22Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth
Nov 03We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth
May 12We're Not Worried About Shanghai Bio-heart Biological Technology's (HKG:2185) Cash Burn
Sep 19Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans
Jun 03Shareholder Returns
| 2185 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -10.9% | -4.7% | -5.3% |
| 1Y | -62.0% | -37.4% | 11.3% |
Return vs Industry: 2185 underperformed the Hong Kong Medical Equipment industry which returned -37.4% over the past year.
Return vs Market: 2185 underperformed the Hong Kong Market which returned 11.3% over the past year.
Price Volatility
| 2185 volatility | |
|---|---|
| 2185 Average Weekly Movement | 12.7% |
| Medical Equipment Industry Average Movement | 10.0% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 19.1% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2185 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2185's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 54 | Philip Wang | www.bio-heart.com |
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People’s Republic of China. It develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis.
Shanghai Bio-heart Biological Technology Co., Ltd. Fundamentals Summary
| 2185 fundamental statistics | |
|---|---|
| Market cap | HK$433.28m |
| Earnings (TTM) | -HK$124.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.3x
P/E RatioIs 2185 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2185 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥115.54m |
| Earnings | -CN¥115.54m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 2185 perform over the long term?
See historical performance and comparison